Patient demographics and ocular characteristics at baseline, by treatment group
| Nepafenac (N=80) | Vehicle (N=80) | p Value | |
|---|---|---|---|
| Age (years) | |||
| Mean (SD) | 68.1 (8.6) | 69.4 (7.6) | 0.31 |
| Min, Max | 49, 90 | 53, 84 | |
| Sex, n (%) | |||
| Male | 51 (63.8) | 44 (55.0) | 0.26 |
| Female | 29 (36.3) | 36 (45.0) | |
| Race, n (%) | |||
| Asian | 6 (7.5) | 5 (6.3) | 0.97 |
| Black or African-American | 1 (1.3) | 0 (0.0) | |
| Native Hawaiian or Other | 2 (2.5) | 2 (2.5) | |
| Pacific Islander | 0 (0.0) | 0 (0.0) | |
| Other | 2 (2.5) | 2 (2.5) | |
| White | 69 (86.3) | 71 (88.8) | |
| NPDR classification, n (%) | |||
| Mild NPDR | 58 (72.5) | 57 (71.3) | 1.0 |
| Moderate NPDR | 21 (26.3) | 22 (27.5) | |
| Severe NPDR | 1 (1.3) | 1 (1.3) | |
| BCVA* (ETDRS letters) | |||
| Mean (SD) | 63.3 (12.8) | 65.2 (12.1) | 0.34 |
| Min, Max | 13, 84 | 28, 84 | |
| CSMT (µm) | |||
| Mean (SD) | 268.8 (29.0) | 276.8 (23.2) | 0.06 |
| Min, Max | 182, 371 | 224, 364 | |
*Baseline BCVA values based on 79 patients in the nepafenac group and 79 patients in the vehicle group.
Nepafenac=nepafenac ophthalmic suspension, 0.1%; Vehicle=nepafenac ophthalmic suspension, vehicle.
BCVA, best-corrected visual acuity; CSMT, central subfield macular thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; NPDR, non-proliferative diabetic retinopathy.